Could brain tumor patients stop seizure meds sooner?
NCT ID NCT06442748
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether brain tumor patients who have been seizure-free for 6 months on levetiracetam can safely stop the drug earlier than the standard 2-3 years. 604 adults with primary brain tumors and controlled seizures will be randomly assigned to stop levetiracetam after 6 months or continue for 2-3 years. The goal is to see if a shorter course prevents seizures just as well while reducing side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
levetiracetam
What this could lead to
If successful, this could show that a shorter course of levetiracetam is just as effective as a longer one, reducing side effects and medication burden for brain tumor patients.
What could go wrong
This is a large phase 3 trial, but it is still possible that stopping levetiracetam early leads to more seizures. The results may not apply to all brain tumor types or patients on other medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEIZURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Manipal Academy of Higher Education
NOT_YET_RECRUITINGUdupi, Karnataka, 576104, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tata Memorial Centre
RECRUITINGMumbai, Maharashtra, 400012, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact